Global Oncolytic Virus Immunotherapy Market & Clinical Trials Insight 2028 Report Overview:
- Global Oncolytic Virus Immunotherapy Therapy Market Overview
- Global Oncolytic Virus Immunotherapy Therapy Market Opportunity: > USD 1 Billion By 2028
- Insight On More Than 180 Oncolytic Virus Immunotherapies In Clinical Trials
- Patent Information On More Than 60 Therapies in Clinical Trials
- IMLYGIC, Oncorine, Delytact: Availability, Dosage & Price Analysis
- Oncolytic Virus Immunotherapy Clinical Pipeline By Country, Phase, Indication, Organization, Patient Segment
- Oncolytic Virus Immunotherapy Application By 10 Cancer
- Recent Strategic Partnerships, Collaborations, Mergers & Acquisitions
Download Report:
The discovery of oncolytic viruses having the potential to be used in cancer therapy happened decades ago, but it was not until recently that oncolytic virus therapies have begun to move through the channel of preclinical studies towards clinical trials. Using oncolytic viruses to stimulate the immune system is a unique and different technique which truly depicts how advanced science and cancer treatment have become. The ongoing use of immunotherapy in combination with organisms like oncolytic viruses has shown additive and synergistic effects with conventional treatment options like chemotherapy and radiotherapy, all of which are expected to allow the approval of more oncolytic virus therapies in the coming years.
Oncolytic virus immunotherapy is becoming more widely accepted, which has prompted extensive testing of this strategy in clinical trials. Positive results were seen in the early stages of these trials, increasing the likelihood that this therapy will be made available in the commercial market; however, their efficacy must first be established in clinical studies. Transgene, a biotech company that specializes in developing virus-based immunotherapies for the treatment of cancer, recently announced that the National Agency for the Safety of Medicines and Health Products of France had approved its application for a clinical trial. This will allow Transgene to move forward with the phase I clinical trial of its candidate TG6050, a novel oncolytic virus that will be given intravenously to patients with advanced non-small cell lung cancer (NSCLC).
The clinical use of oncolytic virus immunotherapy is emerging as a substitute to modify tumor microenvironment from a cold state to a hot state, where the immune system is able to kill abnormal tumor cells. The ability of oncolytic viruses to selectively target certain cells in the tumor microenvironment has enabled researchers to find their application in a number of solid tumors. Additionally, combining oncolytic viruses with existing therapeutics approaches like immunotherapy might lead to enhancement in their activity. However, there remain numerous medical gaps in the area, but extensive research and development has drastically raised the innovative ability in the method.
The development and emergence of therapies like immunotherapy and oncolytic virus therapy and the combination of these approaches has been nothing short of revolutionary for cancer treatment. The combinatorial use of these methods can prove to be an effective approach that addresses cancer resistance, representing an exciting avenue of cancer therapy. The systemic delivery of oncolytic viruses using standard intravenous infusions has not been sufficient to achieve potential effect on metastatic tumor beds. To confront complications like this, companies over the world have merged research and development techniques to significantly develop ways that can produce better results.
Imugene, a biopharmaceutical startup in the early stages, has achieved great strides in its mission to cure and eliminate tumors in cancer patients. For metastatic advanced solid tumors (MAST), a phase I trial is assessing the security of the cancer-killing virus VAXINIA. An oncolytic virus asset of the company used in the study has been found to reduce the size of cancerous tumors in preclinical and experimental models of colon, lung, breast, ovarian, and pancreatic cancer. Additionally, the company presented the results from preclinical research done on onCARlytics (CF33-CD19) oncolytic virus combinations in October 2022.
Oncolytic virus immunotherapy is proving to be a novel and promising therapeutic option for patients with cancer which has become resistant to traditional and conventional therapies. This is an innovative biological therapeutic approach. The approval of Talimogene laherparepvec (T-VEC) from Amgen in 2015 by the European Medical Agency (EMA) as well as the US FDA for the management of unresectable metastatic melanoma has opened a new venue of cancer treatment which utilizes live virus’ to specifically target the malignant tumor cells.
This report gives a detailed view of the current market scenario of oncolytic virus immunotherapy with insights on the developing candidates under clinical trials as well as a detailed analysis of the already commercially available oncolytic virus immunotherapies. Our report aims to justify the potential shift the market will see when more drugs based on oncolytic virus immunotherapy enter the market and how the regional markets will be affected by the same.
Contact:
Neeraj Chawla
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com